OrthoPediatrics (NASDAQ:KIDS) Given New $40.00 Price Target at BTIG Research

OrthoPediatrics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • BTIG raised its price target on OrthoPediatrics from $30 to $40 and reiterated a Buy rating, implying 27.35% upside from the stock’s current price.
  • Analyst sentiment is broadly positive: the consensus rating is Moderate Buy, with an average price target of $32. Seven analysts rate the stock Buy, one Hold, and one Sell.
  • In its latest quarter, OrthoPediatrics reported revenue of $72.66 million, above expectations, but EPS of -$0.23, missing consensus by $0.02.
  • MarketBeat previews the top five stocks to own by December 1st.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) had its price objective raised by equities researchers at BTIG Research from $30.00 to $40.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. BTIG Research's price objective points to a potential upside of 27.35% from the stock's current price.

A number of other equities research analysts have also recently commented on the stock. TD Cowen raised their price target on shares of OrthoPediatrics from $23.00 to $28.00 and gave the stock a "buy" rating in a report on Wednesday, October 28th. Lake Street Capital upped their price objective on shares of OrthoPediatrics from $34.00 to $38.00 and gave the company a "buy" rating in a report on Wednesday, October 28th. Piper Sandler reiterated an "overweight" rating and issued a $30.00 price target (up from $25.00) on shares of OrthoPediatrics in a report on Wednesday, October 28th. Truist Financial lifted their price objective on shares of OrthoPediatrics from $22.00 to $28.00 and gave the company a "hold" rating in a report on Wednesday, October 28th. Finally, Stifel Nicolaus increased their price target on OrthoPediatrics from $24.00 to $27.00 and gave the company a "buy" rating in a research report on Wednesday, October 28th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, OrthoPediatrics has a consensus rating of "Moderate Buy" and an average price target of $32.00.

Check Out Our Latest Report on OrthoPediatrics

OrthoPediatrics Trading Down 0.3%

NASDAQ KIDS opened at $31.41 on Wednesday. The business has a 50 day simple moving average of $25.44 and a 200 day simple moving average of $20.44. OrthoPediatrics has a one year low of $14.42 and a one year high of $34.53. The stock has a market capitalization of $820.12 million, a P/E ratio of -21.96 and a beta of 0.90. The company has a debt-to-equity ratio of 0.29, a current ratio of 4.55 and a quick ratio of 2.00.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.02). The business had revenue of $72.66 million for the quarter, compared to the consensus estimate of $68.50 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 12.83%. Research analysts expect that OrthoPediatrics will post -1.09 earnings per share for the current year.

Insiders Place Their Bets

In other OrthoPediatrics news, major shareholder Squadron Capital Llc sold 302,369 shares of the business's stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the sale, the insider directly owned 6,201,764 shares in the company, valued at $130,299,061.64. The trade was a 4.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Jennifer Pritzker sold 302,369 shares of the company's stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the transaction, the insider directly owned 6,201,764 shares in the company, valued at $130,299,061.64. This represents a 4.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 2,100,000 shares of company stock valued at $46,747,931 over the last ninety days. 32.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On OrthoPediatrics

Several institutional investors have recently added to or reduced their stakes in the business. HighMark Wealth Management LLC bought a new position in shares of OrthoPediatrics in the third quarter worth $111,000. Aquatic Capital Management LLC purchased a new position in shares of OrthoPediatrics in the third quarter valued at $25,000. Goldman Sachs Group Inc. grew its position in shares of OrthoPediatrics by 16.5% in the third quarter. Goldman Sachs Group Inc. now owns 354,958 shares of the company's stock valued at $7,905,000 after purchasing an additional 50,246 shares in the last quarter. Palumbo Wealth Management LLC bought a new stake in shares of OrthoPediatrics during the 3rd quarter valued at $454,000. Finally, Advisors Asset Management Inc. bought a new stake in shares of OrthoPediatrics during the 3rd quarter valued at $228,000. 69.05% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

(Get Free Report)

OrthoPediatrics Corp. develops and markets orthopedic implants and instruments designed specifically for children and adolescents. Its products support surgeons treating a range of pediatric conditions, including fractures, spinal deformities, limb-length differences and other orthopedic disorders. The company's portfolio includes systems for trauma and deformity correction, scoliosis treatment, limb lengthening and external fixation, as well as specialized surgical instruments. It also provides related education and support for pediatric orthopedic surgeons and care teams.

Read More

Analyst Recommendations for OrthoPediatrics (NASDAQ:KIDS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in OrthoPediatrics Right Now?

Before you consider OrthoPediatrics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.

While OrthoPediatrics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines